Եվրոպական Միություն - հունարեն - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - Ανοσοκατασταλτικά - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Եվրոպական Միություն - հունարեն - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - Λευχαιμία, λεμφοκυτταρική, χρόνια, Β-κυτταρική - Αντινεοπλασματικοί παράγοντες - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Եվրոպական Միություն - հունարեն - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - lopinavir, ritonavir - hiv Λοιμώξεις - antivirals for systemic use, protease inhibitors - Το kaletra ενδείκνυται σε συνδυασμό με άλλα αντιρετροϊκά φαρμακευτικά προϊόντα για τη θεραπεία της ανθρώπινης ανοσοανεπάρκειας (hiv-1) που έχουν μολυνθεί ενήλικες, εφήβους και παιδιά ηλικίας από 14 ημέρες και άνω. Η επιλογή του kaletra για τη θεραπεία αναστολέα πρωτεάσης hiv-1 οροθετικούς ασθενείς θα πρέπει να βασίζεται στην ατομική δοκιμή αντοχής και το ιστορικό της θεραπείας των ασθενών.

Եվրոպական Միություն - հունարեն - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - Αρθρίτιδα, ρευματοειδή - Ανοσοκατασταλτικά - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Եվրոպական Միություն - հունարեն - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ritonavir - hiv Λοιμώξεις - Αντιιικά για συστηματική χρήση - Το ritonavir ενδείκνυται σε συνδυασμό με άλλους αντιρετροϊκούς παράγοντες για τη θεραπεία ασθενών με hiv-1 (ενήλικες και παιδιά ηλικίας δύο ετών και άνω).

Հունաստան - հունարեն - Εθνικός Οργανισμός Φαρμάκων

abbvie ΦΑΡΜΑΚΕΥΤΙΚΗ ΑΝΩΝΥΜΗ ΕΤΑΙΡΕΙΑ Δ.Τ. abbvie a.e. - ΡΙΜΠΑΒΙΡΊΝΗ - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 200mg/tab - 0036791045 - ribavirin - 200.000000 mg - ribavirin

Հունաստան - հունարեն - Εθνικός Οργανισμός Φαρμάκων

abbvie ΦΑΡΜΑΚΕΥΤΙΚΗ ΑΝΩΝΥΜΗ ΕΤΑΙΡΕΙΑ Δ.Τ. abbvie a.e. - ΡΙΜΠΑΒΙΡΊΝΗ - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 600mg/tab - 0036791045 - ribavirin - 600.000000 mg - ribavirin

Հունաստան - հունարեն - Εθνικός Οργανισμός Φαρμάκων

abbvie ΦΑΡΜΑΚΕΥΤΙΚΗ ΑΝΩΝΥΜΗ ΕΤΑΙΡΕΙΑ Δ.Τ. abbvie a.e. - ΡΙΜΠΑΒΙΡΊΝΗ - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 400mg/tab - 0036791045 - ribavirin - 400.000000 mg - ribavirin

Հունաստան - հունարեն - Εθνικός Οργανισμός Φαρμάκων

abbvie ΦΑΡΜΑΚΕΥΤΙΚΗ ΑΝΩΝΥΜΗ ΕΤΑΙΡΕΙΑ Δ.Τ. abbvie a.e. Μαρίνου Αντύπα 41-45,, 141 21 141 21, Νέο Ηράκλειο 214 4165 555 - paricalcitol - soft.caps (ΚΑΨΑΚΙΟ, ΜaΛΑΚΟ) - 1mcg/cap - paricalcitol 1mcg - paricalcitol

Հունաստան - հունարեն - Εθνικός Οργανισμός Φαρμάκων

abbvie ΦΑΡΜΑΚΕΥΤΙΚΗ ΑΝΩΝΥΜΗ ΕΤΑΙΡΕΙΑ Δ.Τ. abbvie a.e. Μαρίνου Αντύπα 41-45,, 141 21 141 21, Νέο Ηράκλειο 214 4165 555 - paricalcitol - soft.caps (ΚΑΨΑΚΙΟ, ΜaΛΑΚΟ) - 2mcg/cap - paricalcitol 2mcg - paricalcitol